12
Participants
Start Date
February 19, 2025
Primary Completion Date
May 15, 2026
Study Completion Date
August 31, 2026
Letermovir
Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.
RECRUITING
University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
University of Minnesota - Pediatric Infectious Disease, Minneapolis
RECRUITING
Louisiana State University Health Shreveport - Infectious Diseases, Shreveport
RECRUITING
Children's of Alabama Child Health Research Unit (CHRU), Birmingham
RECRUITING
Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease, Washington D.C.
RECRUITING
Emory University School of Medicine, Atlanta
RECRUITING
SUNY Upstate Medical University Hospital - Pediatrics, Syracuse
RECRUITING
Nationwide Children's Hosp.-Neonatology-Ctr. for Perinatal Rsrch., Columbus
RECRUITING
University of Texas Southwestern Medical Center - Pediatrics, Dallas
National Institute of Allergy and Infectious Diseases (NIAID)
NIH